Reduction of immunoglobulin levels during imatinib therapy of chronic myeloid leukemia

Leukemia Research

Volumn 32, Issue 1, 2008, Pages 191-192

  Cervetti, Giulia ^a   Carulli, Giovanni ^a   Galimberti, Sara ^a   Azzarà, Antonio ^a   Cannizzo, Elisa ^a   Buda, Gabriele ^a   Orciuolo, Enrico ^a   Petrini, Mario ^a  

^a Transplants and New Technologies in Medicine   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; IMATINIB; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERFERON; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; STEM CELL FACTOR;

ADULT; B LYMPHOCYTE; CASE REPORT; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; DRUG TOLERABILITY; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; LETTER; MALE; PERIPHERAL LYMPHOCYTE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TREATMENT RESPONSE;

ADULT; AGAMMAGLOBULINEMIA; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PYRIMIDINES;

EID: 36048939656     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.02.013     Document Type: Letter

References (6)

1. Faderl S., Talpaz M., Estrov Z., et al. Chronic myelogenous leukaemia: biology and therapy. Ann Intern Med 131 (1999) 207-219
2. Buchdunger E., Matter A., and Druker B.J. BCR-ABL inhibition as a modality of CML therapeutics. Biochim Biophys Acta 1551 (2001) M11-M18
3. Druker B. STI571 (Gleevec/Glivec, imatinib) versus interferon (IFN) + cytarabine as initial therapy for patients with CML: results of a randomized study. Proceedings of the 38th Annual Meeting of the American Society of Clinical Oncology, vol. 21. Orlando, USA (2002) [abstract 1]
4. Mothy M., Blaise D., Olive D., and Gaugler B. Imatinib: the narrow line between immune tolerance and activation. Trends Mol Med 11 (2005) 397-402
5. Steegmann J.L., Moreno G., Alàez C., Osorio S., Granda A., De La Càmara R., et al. Chronic myeloid leukemia patients resistant to or intolerant of interferon α and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. Haematologica 88 (2003) 762-768
6. Bocchia M., Abruzzese E., Forconi F., Ippoliti M., Trawinska M.M., Pirrotta M.T., et al. Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukaemia. Leukemia 20 (2006) 142-143